Atlas Trials

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Clinical trial NCT07093554 · RECRUITING

Trial details

NCT number
NCT07093554
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapse Multiple MyelomaRefractory Multiple Myeloma
Start date
2025-12-02
Primary completion
2027-07-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.